GSK343 decreased tumor stemness. by Laura V. Bownes (10276762)

“…Treatment with GSK343 significantly decreased tumorsphere formation by both the COA3 (A) and COA6 (B) cells, representing a decrease in stem cell-like phenotype. …”

A decrease in CD44+ cells in response to hypoxia. by Daniel V. Brown (3797809)

Loss of Prox1a decreases PR production at 120 hours post-ablation. by Kellie Veen (17343374)

CD47 expression is decreased in hematopoietic progenitor cells in patients with myelofibrosis by A. Nonino (6072632)

“…We compared CD47 expression in hematopoietic stem and progenitor cells of patients with MF and controls and found it to be decreased in progenitors of MF. …”

<i>Kdm6a</i> conditional KO mice have decreased repopulating potential in serial competitive transplantation assays. by Ling Tian (107492)

“…The respective curves showed a decreased repopulation potential for all three cohorts of <i>Kdm6a</i> conditional KO mice, which was most pronounced in KO-F mice. …”

siRNA-mediated APP-BP1 knock-down significantly decreases BrdU-incorporated fetal neural stem cells. by Yuyoung Joo (236048)

Effectiveness of interventions to decrease hesitancy. by Maximilian Nicolaus Burger (12969212)

BMT decreases HFD-induced weight gain associated with decreased preadipocyte number and insulin secretion by Saeed Katiraei (3956147)

“…In conclusion, the reduction in HFD-induced obesity after BMT in mice is at least partly due to alterations in the adipose tissue cell pool composition as well as to a decreased pancreatic secretion of the anabolic hormone insulin. …”

Rapamycin decreases Schwann cell markers, whereas statin induces Schwann cell markers. by Andrea Preitschopf (629851)

STAT3 inhibition in human neural stem cells leads to a decrease in neurosphere formation and proliferation, and an upregulation of Jmjd3 expression. by Maureen M. Sherry-Lynes (3911521)

Aged blood factors decrease cellular responses associated with delayed gingival wound repair by María Paz Saldías (4430032)

Subjects:

H-MSCs^WT decrease myofibroblasts in peri-infarction region. by Panpan Chen (307628)

Subjects:

Decreased ISCs and increased goblet cells after intestinal specific loss of MLL1. by Neha Goveas (11790822)

“…<p><b>(A)</b> Kaplan-Meier survival curve. Tamoxifen was given by gavage for 6 days to mice with the genotype <i>Mll1</i>^{<i>FC/+; Vil-Cre-ERT2/+</i>} (n = 12) and <i>Mll1</i>^{<i>FC/FC; RC/+</i>} (n = 18). …”

Naloxone reverses morphine increased-caspase-3 activity, neuronal differentiation and decreased NPC expression. by Dafna Willner (605895)

“…Morphine 13 =  Morphine 13 µM; Naloxone 50 =  Naloxone 50 µM (<b>6A, 6B</b>).</p>…”

Decrease of 4 Asp isomers at 70°C. by Kenzo Aki (386666)

“…<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0058515#pone-0058515-g007" target="_blank">Figure 7a:</a> decrease of L-α-Asp with incubation of T6-Lα peptide at 70°C. …”

Prolonged treatment with oxytocin does not decrease the neural stem cell pool. by Arvind Palanisamy (3159156)

The decrease in blood flow disrupts CV pruning. by Lin Wen (557398)

MBCD decreased stemness in MDA-MB-231. by Ankit Sharma (578833)

“…<p>(<b>A</b>) Colony formation assay was performed. MDA-MB-231 cells were plated at low density (1000 cells/well) in 6 well plates. …”

Testicular involution prior to sex change in gilthead seabream is characterized by a decrease in DMRT1 gene expression and by massive leukocyte infiltration-6 by Sergio Liarte (75701)

“…Scale bar = 25 μm (,) and 50μm (). Sg, Spermatogenesis; S, spawning; PS, post-spawning; TI, testicular involution; SG, spermatogonia cysts; PSG, primary spermatogonia cysts; SC, spermatocytes cysts; SZ, spermatozoa; PTI, peripheral testicular area in the involution stage; ITI, internal testicular area in the involution stage; OV, ovarian area; (arrow), spermatogonia stem cell; (arrow heads), eosinophilic cells; (white arrows), efferent duct; (asterisk), necrotic areas.…”

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”